Get started
Author

Guillaume Béziat

Observed names: G. Beziat, Guillaume Beziat
ORCID: 0000-0001-9135-6157
Observed ORCID: 0000-0001-9135-6157
OpenAlex ID: A5071469679
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data
2020 · Guillaume Beziat, Loïc Ysebaert · OncoTargets and Therapy · 18
PDF
Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
2020 · Guillaume Beziat, Martin Gauthier, et al. · Clinical Case Reports · 17
PDF
Dactinomycin in acute myeloid leukemia with NPM1 mutations
2020 · Guillaume Beziat, Suzanne Tavitian, et al. · European Journal Of Haematology · 14
Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature
2019 · Guillaume Beziat, Loïc Ysebaert, et al. · Leukemia Research · 11
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient
2019 · Guillaume Beziat, Suzanne Tavitian, et al. · Case Reports in Hematology · 10
PDF
CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
2024 · Laura Aubin, Rúben Vilas Boas, et al. · American Journal of Hematology · 6
PDF
French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma
2023 · Benjamin Hebraud, Miguel Granell, et al. · Blood · 6
Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations
2019 · Guillaume Beziat, Suzanne Tavitian, et al. · Blood · 5
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
2023 · Thibault Comont, Maud D'Aveni, et al. · Blood · 4
Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma
2025 · Jules Higué, Gaetan Basile, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Pathologies malignes et drépanocytose, un nouveau challenge ?
2021 · J. Guiraud Chaumeil, T. Comont, et al. · La Revue de Médecine Interne · 2
Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
2026 · Léopoldine Lapierre, Lucie Laemmel, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension
2025 · Loïc Ysebaert, Caroline Protin, et al. · Journal of Hypertension · 1
French Regional Experience of Pre-CAR-T Cells Lymphodepleting Chemotherapy Outcourced in the Patient's Referring Center
2024 · Anne Dumont, Guillaume Beziat, et al. · Blood · 1
PDF
Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again
2024 · Jules Higué, Gaetan Basile, et al. · Blood · 1
Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
2022 · Guillaume Beziat, Suzanne Tavitian, et al. · Journal of Contemporary Brachytherapy · 1
PDF
Pulmonary mucormycosis following autologous hematopoietic stem cell transplantation for rapidly progressive diffuse cutaneous systemic sclerosis: A case report
2020 · Xavier Boumaza, Lucie Lelièvre, et al. · Medicine · 1
A Novel Molecular Etiology of Paradoxical Hereditary Thrombocytosis Caused by Germline JAK2 Loss‐of‐Function
2026 · Guillaume Beziat, Elodie Rosa, et al. · American Journal of Hematology
PDF
Partial Nuclear Extrusion in Chronic Lymphocytic Leukemia Observed to Be an In Vitro Artefact
2025 · Rima Chatila, Guillaume Beziat, et al. · American Journal of Hematology
PDF
To be hematopoietic, or not to be: That is the neoplastic cell's question
2023 · Mathias Chea, Jill Corre, et al. · American Journal of Hematology
PDF
Works count: 20
Citation count: 101
H-index: 6
I10-index: 5
Year
Topic
Type